BGB-A317-A1217-202
Completed
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
BeOne Study ID 
BGB-A317-A1217-202
ClinicalTrials.gov ID
EudraCT Number
2020-004657-77
China Drug Trials ID
CTR20210588
Study Overview
Sex:
Female
Age: 18 Years / N/A
Study Documents
Study Protocol Statistical Analysis PlanStudy Overview
Sex:
Female
Age: 18 Years / N/A